The latest price target for Addex Therapeutics (NASDAQ:ADXN) was reported by HC Wainwright & Co. on October 2, 2024. The analyst firm set a price target for $30.00 expecting ADXN to rise to within 12 months (a possible 296.83% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Addex Therapeutics (NASDAQ:ADXN) was provided by HC Wainwright & Co., and Addex Therapeutics reiterated their buy rating.

The last upgrade for Addex Therapeutics Ltd happened on July 31, 2024 when HC Wainwright & Co. raised their price target to $30. HC Wainwright & Co. previously had a neutral for Addex Therapeutics Ltd.

The last downgrade for Addex Therapeutics Ltd happened on June 23, 2022 when HC Wainwright & Co. changed their price target from N/A to N/A for Addex Therapeutics Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Addex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Addex Therapeutics was filed on October 2, 2024 so you should expect the next rating to be made available sometime around October 2, 2025.

While ratings are subjective and will change, the latest Addex Therapeutics (ADXN) rating was a reiterated with a price target of $30.00 to $30.00. The current price Addex Therapeutics (ADXN) is trading at is $7.56, which is out of the analyst’s predicted range.